AUTH/3028/3/18: Ex-Employee v AbbVie — Synagis poster attribution and uncertified case studies

📅 2018 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3028/3/18
ComplainantEx-employee (contactable)
CompanyAbbVie
ProductSynagis (palivizumab)
Main issuesDisclosure of company involvement in poster; uncertified case-study (Pathways) document used at promotional meeting(s)
Applicable Code year2016
Complaint received23 March 2018
Case completed17 October 2018
Breach clauses9.1, 9.10, 14.1
No breach clauses2, 15.2
SanctionsUndertaking received

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A contactable ex-employee complained about (1) the production and promotion of an Embrace Stars poster and (2) the use of case studies at regional Embrace meetings.
  • The poster related to Synagis (palivizumab) for prevention of serious lower respiratory tract disease requiring hospitalisation caused by RSV in high-risk children.
  • The poster carried the declaration: “This poster has been reviewed for compliance purposes by AbbVie with no influence on the content/opinions being presented”.
  • The complainant alleged AbbVie’s involvement went beyond compliance review (including edits via a communications agency and involvement of an AbbVie representative), and that the poster was presented as health-professional authored.
  • The complainant also alleged that case studies were used/presented at meetings without going through the company’s approval/certification process (referred to as the Zinc process).
  • During the process, additional evidence included a draft poster with track changes/comments and later an email from a nurse referenced as an author.
⚖️

Outcome

  • Breach: Clause 9.10 — AbbVie’s declaration on the poster did not accurately reflect its involvement and was misleading to readers.
  • Breach: Clause 9.1 — high standards were not maintained (linked to the misleading declaration/attribution of involvement).
  • Breach: Clause 14.1 — failure to certify the Pathways document (case studies) used in the context of a promotional meeting.
  • No breach: Clause 15.2 — the complainant did not establish, on the balance of probabilities, that it was inappropriate for promotional staff to present case studies as alleged, nor that the representative failed to maintain high standards on the narrow allegation about creating the poster.
  • No breach: Clause 2 — the circumstances did not warrant this particular censure; upheld on appeal.
  • Appeal by the complainant was unsuccessful on Clauses 15.2 and 2; the Appeal Board upheld the Panel’s rulings.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training